490 related articles for article (PubMed ID: 18306243)
1. Adenosine A2A receptor antagonist istradefylline (KW-6002) reduces "off" time in Parkinson's disease: a double-blind, randomized, multicenter clinical trial (6002-US-005).
LeWitt PA; Guttman M; Tetrud JW; Tuite PJ; Mori A; Chaikin P; Sussman NM;
Ann Neurol; 2008 Mar; 63(3):295-302. PubMed ID: 18306243
[TBL] [Abstract][Full Text] [Related]
2. A 12-week, placebo-controlled study (6002-US-006) of istradefylline in Parkinson disease.
Stacy M; Silver D; Mendis T; Sutton J; Mori A; Chaikin P; Sussman NM
Neurology; 2008 Jun; 70(23):2233-40. PubMed ID: 18519872
[TBL] [Abstract][Full Text] [Related]
3. Study of istradefylline in patients with Parkinson's disease on levodopa with motor fluctuations.
Hauser RA; Shulman LM; Trugman JM; Roberts JW; Mori A; Ballerini R; Sussman NM;
Mov Disord; 2008 Nov; 23(15):2177-85. PubMed ID: 18831530
[TBL] [Abstract][Full Text] [Related]
4. Istradefylline as monotherapy for Parkinson disease: results of the 6002-US-051 trial.
Fernandez HH; Greeley DR; Zweig RM; Wojcieszek J; Mori A; Sussman NM;
Parkinsonism Relat Disord; 2010 Jan; 16(1):16-20. PubMed ID: 19616987
[TBL] [Abstract][Full Text] [Related]
5. Istradefylline for Parkinson's disease patients experiencing motor fluctuations: results of the KW-6002-US-018 study.
Pourcher E; Fernandez HH; Stacy M; Mori A; Ballerini R; Chaikin P
Parkinsonism Relat Disord; 2012 Feb; 18(2):178-84. PubMed ID: 22000279
[TBL] [Abstract][Full Text] [Related]
6. Clinical efficacy of istradefylline (KW-6002) in Parkinson's disease: a randomized, controlled study.
Mizuno Y; Hasegawa K; Kondo T; Kuno S; Yamamoto M;
Mov Disord; 2010 Jul; 25(10):1437-43. PubMed ID: 20629136
[TBL] [Abstract][Full Text] [Related]
7. A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study.
Parkinson Study Group
Arch Neurol; 2005 Feb; 62(2):241-8. PubMed ID: 15710852
[TBL] [Abstract][Full Text] [Related]
8. Randomized trial of the adenosine A(2A) receptor antagonist istradefylline in advanced PD.
Hauser RA; Hubble JP; Truong DD;
Neurology; 2003 Aug; 61(3):297-303. PubMed ID: 12913187
[TBL] [Abstract][Full Text] [Related]
9. Sarizotan as a treatment for dyskinesias in Parkinson's disease: a double-blind placebo-controlled trial.
Goetz CG; Damier P; Hicking C; Laska E; Müller T; Olanow CW; Rascol O; Russ H
Mov Disord; 2007 Jan; 22(2):179-86. PubMed ID: 17094088
[TBL] [Abstract][Full Text] [Related]
10. Adding a dopamine agonist to preexisting levodopa therapy vs. levodopa therapy alone in advanced Parkinson's disease: a meta analysis.
Talati R; Baker WL; Patel AA; Reinhart K; Coleman CI
Int J Clin Pract; 2009 Apr; 63(4):613-23. PubMed ID: 19222614
[TBL] [Abstract][Full Text] [Related]
11. Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial.
Holloway RG; Shoulson I; Fahn S; Kieburtz K; Lang A; Marek K; McDermott M; Seibyl J; Weiner W; Musch B; Kamp C; Welsh M; Shinaman A; Pahwa R; Barclay L; Hubble J; LeWitt P; Miyasaki J; Suchowersky O; Stacy M; Russell DS; Ford B; Hammerstad J; Riley D; Standaert D; Wooten F; Factor S; Jankovic J; Atassi F; Kurlan R; Panisset M; Rajput A; Rodnitzky R; Shults C; Petsinger G; Waters C; Pfeiffer R; Biglan K; Borchert L; Montgomery A; Sutherland L; Weeks C; DeAngelis M; Sime E; Wood S; Pantella C; Harrigan M; Fussell B; Dillon S; Alexander-Brown B; Rainey P; Tennis M; Rost-Ruffner E; Brown D; Evans S; Berry D; Hall J; Shirley T; Dobson J; Fontaine D; Pfeiffer B; Brocht A; Bennett S; Daigneault S; Hodgeman K; O'Connell C; Ross T; Richard K; Watts A;
Arch Neurol; 2004 Jul; 61(7):1044-53. PubMed ID: 15262734
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of Istradefylline, an Adenosine A2A Receptor Antagonist, as Adjunctive Therapy to Levodopa in Parkinson's Disease: A Pooled Analysis of 8 Phase 2b/3 Trials.
Hauser RA; Hattori N; Fernandez H; Isaacson SH; Mochizuki H; Rascol O; Stocchi F; Li J; Mori A; Nakajima Y; Ristuccia R; LeWitt P
J Parkinsons Dis; 2021; 11(4):1663-1675. PubMed ID: 34486986
[TBL] [Abstract][Full Text] [Related]
13. A long-term study of istradefylline safety and efficacy in patients with Parkinson disease.
Kondo T; Mizuno Y;
Clin Neuropharmacol; 2015; 38(2):41-6. PubMed ID: 25768849
[TBL] [Abstract][Full Text] [Related]
14. Ten-year follow-up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa.
Hauser RA; Rascol O; Korczyn AD; Jon Stoessl A; Watts RL; Poewe W; De Deyn PP; Lang AE
Mov Disord; 2007 Dec; 22(16):2409-17. PubMed ID: 17894339
[TBL] [Abstract][Full Text] [Related]
15. Istradefylline, an adenosine A₂A receptor antagonist, for patients with Parkinson's Disease: a meta-analysis.
Chen W; Wang H; Wei H; Gu S; Wei H
J Neurol Sci; 2013 Jan; 324(1-2):21-8. PubMed ID: 23085003
[TBL] [Abstract][Full Text] [Related]
16. Zydis selegiline reduces off time in Parkinson's disease patients with motor fluctuations: a 3-month, randomized, placebo-controlled study.
Waters CH; Sethi KD; Hauser RA; Molho E; Bertoni JM;
Mov Disord; 2004 Apr; 19(4):426-32. PubMed ID: 15077240
[TBL] [Abstract][Full Text] [Related]
17. Safety and efficacy of perampanel in advanced Parkinson's disease: a randomized, placebo-controlled study.
Eggert K; Squillacote D; Barone P; Dodel R; Katzenschlager R; Emre M; Lees AJ; Rascol O; Poewe W; Tolosa E; Trenkwalder C; Onofrj M; Stocchi F; Nappi G; Kostic V; Potic J; Ruzicka E; Oertel W;
Mov Disord; 2010 May; 25(7):896-905. PubMed ID: 20461807
[TBL] [Abstract][Full Text] [Related]
18. Zonisamide improves motor function in Parkinson disease: a randomized, double-blind study.
Murata M; Hasegawa K; Kanazawa I;
Neurology; 2007 Jan; 68(1):45-50. PubMed ID: 17200492
[TBL] [Abstract][Full Text] [Related]
19. Ropinirole 24-hour prolonged release: randomized, controlled study in advanced Parkinson disease.
Pahwa R; Stacy MA; Factor SA; Lyons KE; Stocchi F; Hersh BP; Elmer LW; Truong DD; Earl NL;
Neurology; 2007 Apr; 68(14):1108-15. PubMed ID: 17404192
[TBL] [Abstract][Full Text] [Related]
20. Adenosine, adenosine A 2A antagonists, and Parkinson's disease.
Jenner P; Mori A; Hauser R; Morelli M; Fredholm BB; Chen JF
Parkinsonism Relat Disord; 2009 Jul; 15(6):406-13. PubMed ID: 19446490
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
